PER-043-01已完成未知
A 12-month, multicenter, randomized, double-blind, placebo-loaded study to examine the long-term tolerance of Formoterol 10 ug via multi-dose dry powder inhaler (MDDPl), both in twice-daily maintenance therapy and on-demand use added to maintenance therapy, in patients with persistent asthma
OVARTIS BIOSCIENSES PERU S.A.,0 个研究点目标入组 0 人开始时间: 2001年7月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Ambulatory patients, men or women, aged between 13 and 75 years, inclusive.
- •Written informed consent granted by the patient or by a family member or his / her legally authorized guardian / representative.
- •Patients with persistent asthma who present symptoms weekly, with at least one day free of symptoms during the run-in period.
- •FEV1 with a value between 50-79% (inclusive) of the expected.
- •Reversibility documented within the last 12 months, or reversibility demonstrated in Visit 1, 15% or more in FEV1, 30 minutes after inhaling 400 pg of salbutamol.
- •Patients receiving anti-inflammatory treatment for stable asthma during the month prior to Visit 1, and during the run-in period.
排除标准
- •Pregnant women, who breastfeed, or who are of childbearing age and do not practice an acceptable method of contraception (oral, mechanical, subcutaneous or surgical). Any patient who becomes pregnant during the trial must interrupt their participation in it and must be controlled during pregnancy and up to 12 months after giving birth.
- •A respiratory infection within the month prior to Visit 1. Patients who develop a respiratory tract infection during the run-in period should discontinue the trial, but will be allowed to be re-recruited at a later date (at least 1 month after the resolution of the respiratory tract infection).
- •An exacerbation of documented asthma within 4 weeks prior to Visit 1.
- •Clinically relevant diseases (including cardiovascular diseases, arrhythmias, uncontrolled hypertension, hypo and hyperthyroidism, hyperadrenergic state, insulin-dependent diabetes mellitus, neoplasms, and laboratory profiles with pathological significance) The trial of the investigator or staff responsible for Novartis may compromise the safety or adherence of the patient, interfere with the evaluations, or prevent the completion of the trial.
- •Patients with COPD, or patients with a history of smoking of> 10 cartons of cigarettes / year (that is, 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years, etc.).
- •QTc above 0.46 seconds in Visit 1 or 2.
- •A documented result of potasemia below the normal range, obtained in the central laboratory at Visit 1 or, if the result of the central laboratory is not available, a result of a local laboratory at Visit 2.
- •Any antiallergic immunization treatment (desensitization) within the last 6 months.
- •History of adverse reactions to sympathomimetic amines or medication administered by inhalation or any of its components.
- •History of non-adherence to therapeutic regimens and patients considered potentially untrustworthy.
- •History of alcoholism and / or a history of drug addiction.
- •Treatment with any investigational drug within the month prior to Visit 1.
- •Use of nasal or inhaled corticosteroids, cromoglycate, nedocromil or leukotriene receptor antagonists that have been used or discontinued or are subject to any change in the daily dose or administration schedule in the month prior to the visit 1. Patients who require the institution of treatment with these medications during the run-in period will not be randomized. Patients can be re-evaluated once they remain under stable treatment for 1 month.
- •The following medications should not be used between Visit 1 and Visit 7 (except in case of exacerbations). The minimum wash-out periods for use before Visit 1, are detailed below: Oral or parenteral corticosteroids: 1 month, Theophylline (any pharmaceutical form): 72 hours, Anti-cholinergic by inhalation or mouth : 48 hours, long-acting p2 agonists by inhalation or mouth: 4 hours.
- •Other medications excluded: p-blocking agents, quinidine and quinidine-like medications (antiarrhythmics), tricyclic antidepressants or other antidepressants (eg, Prozac®, Zoloft®, etc.), and monoamine oxidase inhibitors, of the month prior to Visit 1.
研究者
相似试验
进行中（未招募）
不适用
A multicenter, double-blind, randomized, 12-month, placebo-controlled study to evaluate the lipid-lowering effect, safety and tolerability of AVE5530 25 mg/day and 50mg/day when added to ongoing stable statin therapy (HMG-CoA reductase inhibitors) in patients with primary hypercholesterolemia.EUCTR2008-001550-41-PTSanofi-Aventis Recherche & Développement1,000
进行中（未招募）
不适用
A multicenter, double-blind, randomized, 12-month, placebo-controlled study to evaluate the lipid-lowering effect, safety and tolerability of AVE5530 25 mg/day and 50mg/day when added to ongoing stable statin therapy (HMG-CoA reductase inhibitors) in patients with primary hypercholesterolemia.Primary HypercholesterolemiaMedDRA version: 11.0Level: LLTClassification code 10060375Term: <Manually entered code. Term in E.1.1>EUCTR2008-001550-41-DESanofi-Aventis Recherche & Développement1,000
进行中（未招募）
1 期
A multicenter, double-blind, randomized, 12-month, placebo-controlled study to evaluate the lipid-lowering effect, safety and tolerability of AVE5530 25 mg/day and 50mg/day when added to ongoing stable statin therapy (HMG-CoA reductase inhibitors) in patients with primary hypercholesterolemia.Primary HypercholesterolemiaMedDRA version: 11.0Level: LLTClassification code 10060375Term: <Manually entered code. Term in E.1.1>EUCTR2008-001550-41-CZSanofi-Aventis Recherche & Développement1,000
进行中（未招募）
不适用
A multicenter, double-blind, randomized, 12-month, placebo-controlled study to evaluate the lipid-lowering effect, safety and tolerability of AVE5530 25 mg/day and 50mg/day when added to ongoing stable statin therapy (HMG-CoA reductase inhibitors) in patients with primary hypercholesterolemia.Primary HypercholesterolemiaMedDRA version: 11.0Level: LLTClassification code 10060375Term: <Manually entered code. Term in E.1.1>EUCTR2008-001550-41-NLSanofi-Aventis Recherche & Développement1,000
进行中（未招募）
1 期
A multicenter, double-blind, randomized, 12-month, placebo-controlled study to evaluate the lipid-lowering effect, safety and tolerability of AVE5530 25 mg/day and 50mg/day when added to ongoing stable statin therapy (HMG-CoA reductase inhibitors) in patients with primary hypercholesterolemia.Primary HypercholesterolemiaMedDRA version: 11.0Level: LLTClassification code 10060375Term: <Manually entered code. Term in E.1.1>EUCTR2008-001550-41-FRSanofi-Aventis Recherche & Développement1,000